Susanna Jacobus
Overview
Explore the profile of Susanna Jacobus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1365
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Obeng-Gyasi S, Graham N, Kumar S, Lee J, Jacobus S, Weiss M, et al.
Blood Cancer J
. 2022 Apr;
12(4):53.
PMID: 35365604
The objective of this study is to examine the association between neighborhood socioeconomic status (nSES) and baseline allostatic load (AL) and clinical trial endpoints in patients enrolled in the E1A11...
2.
Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski R, et al.
J Clin Oncol
. 2019 Oct;
38(11):1126-1137.
PMID: 31652094
Purpose: Observation is the current standard of care for smoldering multiple myeloma. We hypothesized that early intervention with lenalidomide could delay progression to symptomatic multiple myeloma. Methods: We conducted a...
3.
McKay R, Mills H, Werner L, Choudhury A, Choueiri T, Jacobus S, et al.
J Med Internet Res
. 2019 May;
21(5):e12044.
PMID: 31045501
Background: The pace of drug discovery and approvals has led to expanding treatments for cancer patients. Although extensive research exists regarding barriers to enrollment in oncology clinical trials, there are...
4.
Ailawadhi S, Jacobus S, Sexton R, Stewart A, Dispenzieri A, Hussein M, et al.
Blood Cancer J
. 2018 Jul;
8(7):67.
PMID: 29980678
Multiple myeloma (MM) is an incurable hematologic malignancy with disparities in outcomes noted among racial-ethnic subgroups, likely due to disparities in access to effective treatment modalities. Clinical trials can provide...
5.
Pak K, Jacobus S, Uno H
Contemp Clin Trials Commun
. 2018 Apr;
7:224-230.
PMID: 29696190
In randomized-controlled trials, interim analyses are often planned for possible early trial termination to claim superiority or futility of a new therapy. While unblinding is necessary to conduct the formal...
6.
Bullock A, Stuart K, Jacobus S, Abrams T, Wadlow R, Goldstein M, et al.
J Gastrointest Oncol
. 2018 Jan;
8(6):945-952.
PMID: 29299353
Background: There are limited treatment options available for patients with advanced pancreatic ductal adenocarcinoma (PDAC). We conducted a phase II study evaluating the efficacy and safety of capecitabine/oxaliplatin (CAPOX) in...
7.
Tripathi A, Jacobus S, Feldman H, Choueiri T, Harshman L
Clin Genitourin Cancer
. 2017 Jan;
15(3):396-402.
PMID: 28040423
Background: Increases in hemoglobin have been reported in renal cell carcinoma (RCC) patients treated with vascular endothelial growth factor (VEGF) pathway-targeted therapies and have been associated with increased progression-free survival...
8.
McKay R, Jacobus S, Fiorillo M, Ledet E, Cotogna P, Steinberger A, et al.
Clin Genitourin Cancer
. 2016 Sep;
15(2):e289-e298.
PMID: 27651103
Background: Radium-223 has shown clinical efficacy in metastatic castration-resistant prostate cancer. Despite improvement in quality of life and survival, practice patterns and utility of this agent outside the context of...
9.
Mahoney K, Jacobus S, Bhatt R, Song J, Carvo I, Cheng S, et al.
Clin Genitourin Cancer
. 2016 Apr;
14(4):304-313.e6.
PMID: 27036973
Background: Inhibiting VEGF and mammalian target of rapamycin (mTOR) pathways are standard treatment approaches for patients with metastatic renal cell carcinoma (mRCC). Here we report the activity and safety of...
10.
Stewart A, Jacobus S, Fonseca R, Weiss M, Callander N, Chanan-Khan A, et al.
Blood
. 2015 Jul;
126(11):1294-301.
PMID: 26157076
This phase 3 trial (Eastern Cooperative Oncology Group [ECOG] E1A06) compared melphalan, prednisone, and thalidomide (MPT-T) with melphalan, prednisone, and lenalidomide (mPR-R) in patients with untreated multiple myeloma (MM). A...